We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > lenacapavir

News List

Gilead Submits New Drug Application to U.S. Food and Drug Administration for Lenacapavir, an Investigational, Long-Acting Capsid Inhibitor for the Treatment of HIV-1 in People With Limited Therapy Opt drugs
July 08, 2021
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the company completed submission of a New Drug Application (NDA) to the FDA seeking approval of lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor.
Gilead seeks US approval for long-acting HIV drug lenacapavir pharmatimes
July 01, 2021
Gilead has filed its investigational long-acting HIV drug lenacapavir with the US Food and Drug Administration (FDA), seeking approval in patients with multi-drug resistant infection.
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations expresspharma
March 16, 2021
Gilead Sciences and Merck, known as MSD outside the US and Canada, announced that they have entered into an agreement to co-develop and co-commercialise long-acting treatments in HIV that combine Gilead’s investigational capsid inhibitor, lenacapavir ...